NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
South San Francisco
California
94080
United States
Tel: 650-243-5555
Website: http://www.ngmbio.com/
Email: recruiting@ngmbio.com
About NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc. is a private biotech company dedicated to discovering and developing the next generation of medicines for the treatment of serious diseases. Our experienced scientific team has joined forces with an impressive group of industry professionals, Nobel Laureates and other distinguished researchers to form a company where innovation and cutting-edge science has provided the foundation for a robust drug discovery engine. To date, NGM Bio has generated a pipeline of six drug candidates in various stages of development, including NGM282 that recently demonstrated proof-of-concept in a Phase 2 study in non-alcoholic steatohepatitis (NASH). We have many more in preclinical development. In 2015, we entered into a broad, strategic collaboration with Merck that will provide us with the resources and flexibility to pursue our ambitious R&D goals and further extend our pipeline of novel drug candidates.
68 articles with NGM Biopharmaceuticals, Inc.
-
NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology
1/12/2021
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today outlined its key achievements in 2020 and its strategic priorities for 2021.
-
NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock
1/6/2021
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced the pricing of an underwritten public offering of 4,629,630 shares of its common stock at a price to the public of $27.00 per share.
-
NGM Bio Announces Proposed Offering of Common Stock - Jan 04, 2021
1/4/2021
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock.
-
NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors
12/9/2020
LAIR1, through interactions with tumor-associated collagens, may form a stromal checkpoint that imposes signaling-based immune suppression and impedes anti-tumor immunity
-
NGM to Host Virtual R&D Day on December 9, 2020
11/16/2020
Event to showcase NGM’s multi-therapeutic area pipeline,including its oncology portfolio and Geographic Atrophy and NASH programs
-
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual
11/13/2020
--Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study, with no patients experiencing serious adverse events, drug-related AEs, intraocular inflammation or choroidal neovascularization-- --The serum pharmacokinetics (PK) of NGM621 were linear and dose-proportional-- --NGM621 ocular PK/pharmacodynamics (PD) modeling supports potential for up to every eight-week dosing regimen-- --Enrollment of the CATALINA Phase 2 study of NGM621
-
NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results
11/12/2020
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided business highlights and reported financial results for the quarter ended September 30, 2020.
-
NGM Bio to Present at Three Upcoming Investor Conferences
11/11/2020
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at three upcoming investor conferences.
-
NGM Bio to Present Safety and Pharmacokinetics Data from Phase 1 Study of NGM621 in Patients with Geographic Atrophy at American Academy of Ophthalmology (AAO) 2020 Virtual
11/5/2020
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that data from its Phase 1 study of NGM621, a potent anti-complement C3 antibody, will be featured in a poster presentation at the American Academy of Ophthalmology (AAO) 2020 Virtual.
-
NGM Bio Announces Multiple Aldafermin Presentations at Upcoming AASLD The Liver Meeting®, including Late-Breaking Oral Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH
11/4/2020
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that multiple aldafermin presentations, including a late-breaking oral presentation and comprehensive data from its 24-week Phase 2 study (Cohort 4) of aldafermin in patients with non-alcoholic steatohepatitis (NASH), will be featured at AASLD’s The Liver Meeting ® , bei
-
NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4
10/19/2020
ILT2 and ILT4, key myeloid and lymphoid checkpoints, may restrict anti-tumor immunity, enable tumors to evade immune detection and contribute to T cell checkpoint resistance
-
NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study
8/29/2020
The 24-week Phase 2 study met its primary endpoint, achieving a statistically significant reduction in liver fat content (LFC), and robust fibrosis improvement and resolution of NASH, with a favorable safety profile
-
NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH at The Digital International Liver Congress™ (ILC) 2020
8/18/2020
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that comprehensive data from its 24-week Phase 2 study (Cohort 4) of aldafermin in patients with non-alcoholic steatohepatitis (NASH) will be featured in an oral plenary presentation at The Digital International Liver Congress (ILC) 2020, which will be held virtual
-
NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results
8/12/2020
--Sustained progress across clinical development programs spanning liver, retinal and metabolic diseases and cancer-- --Aldafermin continues to advance toward late-stage clinical development in non-alcoholic steatohepatitis (NASH) with ongoing Phase 2b ALPINE 2/3 and ALPINE 4 clinical studies-- --Initiated Phase 2 CATALINA study of NGM621, a complement C3 inhibitory antibody to treat patients with geographic atrophy (GA)-- --$312.1 million in cash, cash equivalents and marketable
-
NGM Bio to Present at Two Upcoming Investor Conferences - July 31, 2020
7/31/2020
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at two upcoming investor conferences.
-
NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
7/27/2020
-- Multicenter, randomized, double-masked, sham-controlled study will evaluate safety and efficacy of intravitreal injections of NGM621 every four or eight weeks for 48 weeks -- -- GA is a progressive, irreversible retinal degenerative disease with no approved therapies -- -- NGM621, a monoclonal antibody, is engineered to potently inhibit complement C3 with the treatment goal of reducing disease progression in patients with GA --
-
NGM Bio Expands Board of Directors with Appointment of Carole Ho, M.D.
6/8/2020
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced the appointment of Carole Ho, M.D. to its Board of Directors. Dr. Ho currently serves as Chief Medical Officer and Head of Development at Denali Therapeutics. “Carole’s background as a physician-scientist with deep industry expertise is ideally suited to NGM’s cu
-
NGM Bio to Present at Two Upcoming Investor Conferences
5/29/2020
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at two upcoming investor conferences.
-
NGM Bio Appoints Siobhan Nolan Mangini as Chief Financial Officer
5/27/2020
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced the appointment of Siobhan Nolan Mangini as Chief Financial Officer (CFO).
-
NGM Bio Provides Business Update and Reports First Quarter 2020 Financial Results
5/13/2020
Initiated Phase 2b ALPINE 4 clinical study of aldafermin (formerly NGM282) in non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (F4 fibrosis)